Introduction：Basic information about CAS 180384-57-0|N-[6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-2-[2-(2H-tetrazol-5-yl)pyridin-4-yl]pyri, including its chemical name, molecular formula, synonyms, physicochemical properties, and safety information, etc.
| Common Name | N-[6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-2-[2-(2H-tetrazol-5-yl)pyridin-4-yl]pyrimidin-4-yl]-5-propan-2-ylpyridine-2-sulfonamide |
|---|
| CAS Number | 180384-57-0 | Molecular Weight | 605.625 |
|---|
| Density | 1.4±0.1 g/cm3 | Boiling Point | 761.2±70.0 °C at 760 mmHg |
|---|
| Molecular Formula | C27H27N9O6S | Melting Point | / |
|---|
| MSDS | / | Flash Point | 414.2±35.7 °C |
|---|
Names
| Name | N-[6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-2-[2-(2H-tetrazol-5-yl)pyridin-4-yl]pyrimidin-4-yl]-5-propan-2-ylpyridine-2-sulfonamide |
|---|
| Synonym | More Synonyms |
|---|
BiologicalActivity
| Description | Tezosentan (RO 610612) is an endothelin (ET) receptor antagonist, with pA2s of 9.5, 7.7 for ETA and ETB receptors, respectively. |
|---|
| Related Catalog | Signaling Pathways >>GPCR/G Protein >>Endothelin ReceptorResearch Areas >>Neurological DiseaseResearch Areas >>CancerResearch Areas >>Cardiovascular Disease |
|---|
| Target | ETA:9.5 (pA2) ETB:7.7 (pA2) |
|---|
| In Vitro | Affinity of Tezosentan for the ET receptors is assessed in different cells and tissues. Tezosentan inhibits the specific 125I-labeled ET-1 binding to ETA receptors with an inhibitory potency (Ki) of 0.3 nM on CHO cells and of 18 nM on membranes of baculovirus-infected insect cells. Similarly, Tezosentan inhibits the specific binding of 125I-labeled ET-1, ET-3, or sarafotoxin S6c to ETB receptors with an inhibitory affinity of 10 to 21 nM. Tezosentan up to a concentration of 1 μM did not exhibit any binding inhibitory activity in 27 radioligand binding assays different from ET binding. On H1 central, 5-hydroxytryptamine2A, and vasopressin V1 receptors, Tezosentan (1 μM) induces a weak inhibition of less than 20%[1]. |
|---|
| In Vivo | In pithed Wistar rats, Tezosentan dose-dependently inhibits the pressor effect of big ET-1 (P<0.001 at all doses). At the lowest dose tested of 1 mg/kg, Tezosentan inhibits the pressor effect of the various doses of big ET-1 by 50 to 80%. Tezosentan has no effect by itself on blood pressure in these pithed rats. Tezosentan is very effective in a rat model of acute renal failure. ET antagonists have been shown to prevent the vasoconstriction and the renal failure that follow acute renal ischemia in rats[1]. |
|---|
| Animal Admin | Rats[1] A pseudocrush syndrome is simulated by injection of i.m. glycerol. A control group does not receive glycerol and is used as a reference. Tezosentan or bosentan for comparison or saline as control is injected as two bolus i.v. doses of 10 mg/kg 1 h and 20 min before glycerol. Rats are allowed to recover for 2 h and then are placed in individual metabolic cages for 48 h. Blood samples withdraw from a catheter placed in the abdominal aorta and urine free of food and feces are collected at 24 and 48 h. Plasma and urinary creatinine levels are measured with a centrifugal analyzer. Renal function is assessed by calculating creatinine clearance at 24 and 48 h after glycerol administration[1]. |
|---|
| References | [1]. Clozel M, et al. Pharmacology of tezosentan, new endothelin receptor antagonist designed for parenteral use. J Pharmacol Exp Ther. 1999 Aug;290(2):840-6. |
|---|
Chemical & Physical Properties
| Density | 1.4±0.1 g/cm3 |
|---|
| Boiling Point | 761.2±70.0 °C at 760 mmHg |
|---|
| Molecular Formula | C27H27N9O6S |
|---|
| Molecular Weight | 605.625 |
|---|
| Flash Point | 414.2±35.7 °C |
|---|
| Exact Mass | 605.180481 |
|---|
| PSA | 208.49000 |
|---|
| LogP | 0.89 |
|---|
| Vapour Pressure | 0.0±2.7 mmHg at 25°C |
|---|
| Index of Refraction | 1.634 |
|---|
| InChIKey | TUYWTLTWNJOZNY-UHFFFAOYSA-N |
|---|
| SMILES | COc1ccccc1Oc1c(NS(=O)(=O)c2ccc(C(C)C)cn2)nc(-c2ccnc(-c3nn[nH]n3)c2)nc1OCCO |
|---|
Synonyms
| N-[6-(2-Hydroxyethoxy)-5-(o-methoxyphenoxy)-2-[2-(1H-tetrazol-5-yl)-4-pyridyl]-4-pyrimidinyl]-5-isopropyl-2-pyridinesulfonamide |
| tezosentan |
| 2-pyridinesulfonamide, N-[6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-2-[2-(1H-tetrazol-5-yl)-4-pyridinyl]-4-pyrimidinyl]-5-(1-methylethyl)- |
| N-{6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-2-[2-(1H-tetrazol-5-yl)pyridin-4-yl]pyrimidin-4-yl}-5-(propan-2-yl)pyridine-2-sulfonamide |
| 2-Pyridinesulfonamide, N-[6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-2-[2-(2H-tetrazol-5-yl)-4-pyridinyl]-4-pyrimidinyl]-5-(1-methylethyl)- |
| N-{6-(2-Hydroxyethoxy)-5-(2-methoxyphenoxy)-2-[2-(1H-tetrazol-5-yl)-4-pyridinyl]-4-pyrimidinyl}-5-isopropyl-2-pyridinesulfonamide |
| N-{6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-2-[2-(2H-tetrazol-5-yl)pyridin-4-yl]pyrimidin-4-yl}-5-(propan-2-yl)pyridine-2-sulfonamide |
| 2-Pyridinesulfonamide,N-(6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-2-(2-(1H-tetrazol-5-yl)-4-pyridinyl)-4-pyrimidinyl)-5-(1-methylethyl) |
| N-{6-(2-Hydroxyethoxy)-5-(2-methoxyphenoxy)-2-[2-(2H-tetrazol-5-yl)pyridin-4-yl]pyrimidin-4-yl}-5-isopropylpyridine-2-sulfonamide |
| Tezosentan [INN] |
| N-(6-(2-Hydroxyethoxy)-5-(2-methoxyphenoxy)-2-(2-(1H-tetrazol-5-yl)-4-pyridinyl)-4-pyrimidinyl)-5-(1-methylethyl)-2-pyridinesulfonamide |
